… 6 (IL‐6) receptor, in patients with coronavirus disease‐2019 (COVID‐19) patients has led to
… efficacy of addition of TOC to standard of care (SOC) versus SOC in patients with COVID‐19. …

… the efficacy outcomes we examined. Because of the width of the confidence intervals for our
efficacy comparisons, however, we cannot exclude the possibility that tocilizumab treatment …

… in treating severe COVID-19 as it … efficacy of tocilizumab treatment in severe COVID-19,
we conducted a systematic review and meta-analysis to clarify this added effect of tocilizumab. …

… , treating critically ill COVID-19 patients remains an issue with … the efficacy of IL-6 inhibitors,
namely tocilizumab have been … ) for the use of tocilizumab in COVID-19. Electronic database …

… tocilizumab use. This review will continuously evaluate the role of tocilizumab in COVID-19 …
assess the impact of COVID-19 disease severity on response to tocilizumab therapy. We also …

… Here, we compare the outcomes at 28 days of a large cohort of patients with severe COVID-19
pneumonia treated with tocilizumab in addition to standard management, with those of …

… trials of tocilizumab have shown mixed results in patients with varying degrees of Covid-19 …
the safety and efficacy of tocilizumab in hospitalized patients with Covid-19 pneumonia who …

… Moderate-certainty evidence shows that tocilizumab reduces the risk of poor outcome and …
COVID-19 patients. This review will continuously evaluate the role of tocilizumab in COVID-19 …

… efficacy and safety of tocilizumab in patients with critical or severe coronavirus disease 2019
(COVID-19)… (Wuhan, China) with confirmed COVID-19 between January 2020 and February …

… the efficacy and safety of tocilizumab in patients hospitalised with COVID-19 pneumonia …
in previous trials and evaluates the efficacy of tocilizumab across subgroups of patients defined …